PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

— PFROST  

Official title:

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03439215
• Other study ID #: FoRT 01/2016
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 13, 2017
• Est. completion date: June 2022

Study information

• Verified date: July 2021
• Source: Fondazione Ricerca Traslazionale
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II study assessing response rate to PF-06463922 in patients with ROS1 translocation resistant to previous crizotinib therapy. Eligible patients will be treated with the study drug until disease progression, unacceptable toxicity or patient refusal. Disease assessment will be performed every 8 weeks according to RECIST criteria.

Description:

PF-06463922 is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration. The results showed that PF-06463922 is most potent against ROS1 and ALK, with selectivity ratios >100-fold for ROS1 over the 204 kinases tested. A recent study has investigated the activity of PF-06463922 against the crizotinib-resistant ROS1G2032R mutation in both recombinant enzyme and cell-based assays. PF-06463922 effectively inhibited the catalytic activity of recombinant ROS1G2032R and the CD74-ROS1G2032R fusion kinase in BaF3 cells. This effect translated directly into an antiproliferative response. These results, together with its exquisite ROS1 potency and ability to suppress the resistant ROS1 mutations, supports the clinical evaluation of PF-06463922 in ROS1-positive NSCLC, including patients who have developed resistance to crizotinib because of the acquired G2032R mutation and/or brain metastases.

This is a phase II study assessing response rate to PF-06463922 in patients with ROS1 translocation resistant to previous crizotinib therapy. Eligible patients will be treated with the study drug until disease progression, unacceptable toxicity or patient refusal. Disease assessment will be performed every 8 weeks according to RECIST criteria.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: June 2022
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent;

2. Male or female patient ages = 18 years;

3. Histologically/cytologically confirmed diagnosis of NSCLC with evidence of ROS1 rearrangement;

4. Possibility to perform a new tumor biopsy or tumor tissue collected at the time or after crizotinib failure;

5. Patient pretreated with crizotinib with evidence of disease progression during crizotinib therapy;

6. At least one radiological measurable disease according to RECIST criteria;

7. At least 1 previous standard chemotherapy regimen;

8. Performance status 0-2 (ECOG);

9. Patient compliance to trial procedures

10. Adequate bone marrow function (ANC = 1.5x109/L, platelets = 100x109/L, haemoglobin > 9 g/dl);

11. Adequate liver function (bilirubin < grade 2, transaminases no more than 3xULN/<5xULN in present of liver metastases);

12. Normal level of alkaline phosphatase and creatinine;

13. If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method [intrauterine contraceptive device (IUD), birth control pills, or barrier device] during and for ninety (90) days after end of treatment.

Exclusion Criteria:

1. No ROS1 rearrangement 2. No previous therapy with crizotinib; 3. No evidence of crizotinib failure; 4. No post-crizotinib tumor tissue available; 5. Absence of any measurable lesions; 6. No previous chemotherapy; 7. Concomitant radiotherapy or chemotherapy; 8. Symptomatic brain metastases; 9. Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma of the skin; 10. Predisposing factors for acute pancreatitis (e.g., uncontrolled hyperglycaemia, current gallstone disease, alcoholism); 11. History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis (but not history of prior radiation pneumonitis); 12. Pregnancy or lactating female; 13. Other serious illness or medical condition potentially interfering with the study.

-

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• Lorlatinib
Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.

Locations

Country	Name	City	State
Italy	Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8	Arezzo
Italy	Azienda Ospedaliera di Rilievo Nazionale "S.G. Moscati"	Avellino
Italy	IRCCS Istituto Tumori Giovanni Paolo II	Bari
Italy	IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari	Genova
Italy	IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica	Meldola	Forlì- Cesena
Italy	Istituto Europeo di Oncologia - Divisione di Oncologia Toracica	Milano
Italy	A.O.U. Policlinico di Modena- Oncologia Ematologia e Malattie Apparato Respiratorio	Modena
Italy	A.O. San Gerardo	Monza
Italy	Istituto Nazionale Tumori IRCCS Fondazione Pascale	Napoli
Italy	Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica	Negrar	Verona
Italy	Istituto Oncologico Veneto IRCCS- UOS Oncologia Toracica UOC. Oncologia Medica 2	Padova
Italy	Casa di Cura La Maddalena- U.O. Oncologia medica	Palermo
Italy	Azienda Ospedaliera Universitaria di Parma- Struttura Complessa di Oncologia Medica	Parma
Italy	Azienda Ospedaliera di Perugia- S.C. Oncologia Medica	Perugia
Italy	Ospedale di Ravenna- Oncologia Medica	Ravenna
Italy	Ospedale "Infermi" Rimini	Rimini
Italy	ASST della Valle Olona - Ospedale di Saronno	Saronno
Italy	A.O.U. San Luigi Gonzaga	Torino
Italy	Azienda ULSS 9 TREVISO-UOC Oncologia Medica	Treviso
Italy	Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica	Verona

Sponsors (2)

Lead Sponsor	Collaborator
Fondazione Ricerca Traslazionale	Clinical research technology Srl

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate to PF-06463922 in patients with ROS1 translocation resistant to crizotinib	Response rate to PF-06463922 in patients with ROS1 translocation resistant to crizotinib	From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
Secondary	Progression-free survival (PFS), The length of time during and after the treatment of a disease,that a patient lives with the disease but it doesn't get worse.	Progression-free survival (PFS) will be calculated from the time between the baseline/start of treatment visit to the time of first occurrence of progressive disease (PD) or death from any cause. Patients who have neither progressed nor died at time of analysis will be censored at the date of last tumor assessment where non progression was documented (i.e. CR, PR or SD)	From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
Secondary	Overall Survival (OS): Time from the start of treatment until death from any cause	Overall survival (OS) will be calculated from the time between the baseline/start of treatment visit to the date of death, irrespective of the cause of death. Patients still alive at the time of analysis will be censored at the date they were last known to be alive	From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Patients will be closely monitored for signs and symptoms of potential adverse events, and will undergo frequent laboratory tests to assess lipids, pancreas, liver, kidney, and haematological function.	From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months
Secondary	Correlation with additional tumor biomarkers in tumor tissue or blood	Correlation with additional tumor biomarkers in tumor tissue or blood	From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 36 months

External Links

•   PFROST trial